New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
05:03 EDTSUPNSupernus announces positive Phase 2b results on SPN-810, advances to development
Supernus Pharmaceuticals received positive top-line results from its Phase 2b study on SPN-810 for the treatment of impulsive aggression in ADHD patients. The study is a multi-center randomized, double-blind, placebo controlled clinical trial in children 6-12 diagnosed with Attention Deficit and Hyperactivity Disorder, or ADHD, and characterized by impulsive aggression that is not controlled by optimal stimulant and psychosocial treatment. A total of 121 patients were randomized in the study across placebo and three doses of SPN-810. SPN-810 was well tolerated throughout the study across all doses. The two serious adverse events that occurred were not drug related. The company will be analyzing the full data-set in depth, and subsequently planning on meeting with the FDA to discuss next steps in the development program and the design and protocol for Phase III clinical trials.
News For SUPN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 18, 2015
06:43 EDTSUPNSupernus price target raised to $20 from $16 at Piper Jaffray
Subscribe for More Information
June 17, 2015
18:55 EDTSUPNSupernus corrects previously disclosed amount of distributed shares
Supernus issued a correction regarding the number of common shares distributed by New Enterprise Associates. Effective following the close of trading on June 15, NEA distributed an aggregate of 3,000,000 shares of Supernus Pharmaceuticals common stock to its partners, not 3,921,000 shares as stated earlier. The NEA funds continue to hold approximately 71% of their original holdings, or 7,647,113 shares, and remain the largest stockholder of Supernus.
07:07 EDTSUPNSupernus announces stock distributin by NEA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use